[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bisirna Therapeutics (Suzhou) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635347","phase-1-safety-pk-and-pd-of-bsa204-in-chinese-adults-with-borderline-elevated-lipoproteina-100635347",false,"NCT07551505","Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of BSA204 Injection in Chinese Adults With Borderline Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Body mass index (BMI) 18 to 30 kg\u002Fm2\n* Fasting triglycerides (TG) ≤ 4.5 mmol\u002FL\n* Borderline elevated fasting lipoprotein(a) \\[Lp(a)\\] levels as defined in the protocol\n* Fasting low-density lipoprotein cholesterol (LDL-C) within the range specified for the assigned dose cohort\n* o clinically significant abnormalities of hepatic or renal function\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History or presence of significant medical conditions\n* Abnormal ECG findings, including a prolonged QTcF interval (\\> 450 msec for males or \\> 470 msec for females)\n* Prior treatment with small interfering RNA (siRNA) or antisense oligonucleotides within 12 months, or recent use of specific lipid-lowering therapies\n* Known allergy to any component of the study drug",true,"ALL","18 Years","55 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) \\[Lp(a)\\].",[28],"Dyslipidemias","NOT_YET_RECRUITING","2026-04-23",{"date":32,"type":33},"2026-04-28","ACTUAL",{"date":35,"type":22},"2026-04-20",{"date":37,"type":22},"2027-12-31",{"name":39,"class":40},"Bisirna Therapeutics (Suzhou) Co., Ltd.","INDUSTRY",2,""]